Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2020 16:15 ET | Source: Liquidia Technologies, Inc.

Liquidia to Report Third Quarter 2020 Financial Results and Provide Corporate Update on November 6, 2020

RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
October 19, 2020 08:30 ET | Source: Liquidia Technologies, Inc.

Liquidia Announces Postponement of Special Meeting of Stockholders

RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
October 14, 2020 09:25 ET | Source: Liquidia Technologies, Inc.

Liquidia Provides Update on U.S. Patent Trial and Appeal Board Decision on Inter Partes Review of Two United Therapeutics’ Tyvaso® Patents

RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
October 05, 2020 07:15 ET | Source: Liquidia Technologies, Inc.

Liquidia Names Gerald M. O’Brien, MD, as Vice President, Pulmonary Clinical Development

RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
September 17, 2020 07:15 ET | Source: Liquidia Technologies, Inc.

Liquidia Announces Special Meeting Date to Approve Proposed Acquisition of RareGen, LLC

RESEARCH TRIANGLE PARK, N.C., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
August 28, 2020 07:15 ET | Source: Liquidia Technologies, Inc.

Liquidia Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treating Pulmonary Hypertension with Dry Powder Treprostinil

RESEARCH TRIANGLE PARK, N.C., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
August 20, 2020 09:15 ET | Source: Liquidia Technologies, Inc.

Liquidia Announces Chief Financial Officer Transition

RESEARCH TRIANGLE PARK, N.C., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
August 10, 2020 07:15 ET | Source: Liquidia Technologies, Inc.

Liquidia Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Received FDA Acceptance of LIQ861 NDA for Review Reported Final Safety and Tolerability Results for LIQ861 INSPIRE TrialAppointed Tushar Shah, M.D. as Chief Medical OfficerAnnounced Definitive...
August 05, 2020 17:30 ET | Source: Liquidia Technologies, Inc.

Liquidia to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
August 05, 2020 07:15 ET | Source: Liquidia Technologies, Inc.

Liquidia Releases Exploratory Endpoint Data from INSPIRE Study at the American Thoracic Society (ATS) Annual Meeting

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...